Introduction
Obesity (defined as a body-mass index (BMI) of >30 kg.m ) and the metabolic syndrome are related conditions that can be 2 − considered as precursors of T2D and increases the risk of developing this disease by >20-fold ( ). Although these Willett et al. 1999 conditions clearly have a genetic component, as indicated by the high prevalence in certain ethnic group, the rapid increase in the prevalence of these conditions in populations throughout the world suggests the contribution of environmental factors. A widely accepted explanation for the increasing prevalence of these conditions lays on the frequent consumption of processed foods with high energy and low fibers content and the reduction in physical exercise due to sedentary lifestyle in modern urban environment. Thus, obesity arises due to an imbalance between energy intake and energy expenditure where caloric excess accumulates preferentially as lipids in adipose tissue but also into muscle and liver. Disruption of energy balance has led to an increased prevalence of T2D and related comorbidities such as coronary heart disease, heart failure, hypertension and renal failure ( ). Wing et al. 2001 Type 2 diabetes (T2D) has a high prevalence worldwide and its treatment produces considerable costs for the health budgets.
Prevention and management of T2D has become a major public health challenge around the world. Diabetes is defined by a fasting plasma glucose higher than 7 mM ( ). T2D is characterized by altered lipid and glucose metabolism (fasting or Alberti and Zimmet 1998 postprandial hyperglycaemia, dyslipidemia) as a consequence of combined insulin resistance in skeletal muscle, liver and adipose tissue and relative defects of insulin secretion by -cells that may arise due to an imbalance between energy intake and expenditure ( β
Saltiel and
). Insulin is the primary anabolic hormone that stimulates uptake and storage of fuel substrates, while inhibiting substrate Kahn 2001 production in peripheral tissues ( ). It lowers blood glucose levels by facilitating glucose uptake, mainly into skeletal Kahn et al. 2006 muscle and fat tissue, and by inhibiting endogenous glucose production in the liver. Insulin resistance occurs when a normal dose of insulin is unable to elicit its metabolic responses. Peripheral insulin resistance is associated with lipid partitioning in specific compartments, i.e. muscle and liver, more than with obesity ( ; ). In the natural history of per se DeFronzo and Tripathy 2009 Unger 1995 type 2 diabetes, pancreatic -cells initially compensate for insulin resistance by increasing insulin secretion, but with time, progressive β β -cell failure leads to insulin deficiency, and hyperglycaemia ensues ( ). Fonseca 2009 Lifestyle intervention is now recognized as the first-line strategy for the management of T2D and remains important for optimization of metabolic control. This is supported by observational studies and clinical trials comparing the respective effects of diet, drugs or exercise, in persons at high risk for type 2 diabetes ( ;sulphonylureas, DPP-4 inhibitors, and GLP-1 analogs. The currently available classes of oral agents differ in mechanism and duration of action, and the degree to which they lower blood glucose and their side-effect profile (including hypoglycaemia, weight gain, dema, fractures, lactic acidosis, and gastrointestinal intolerance). Because it is recognized that T2D is a progressive disease worsening with time, all available drugs can be used alone or in varied associations.
There is a pressing need to develop new therapeutic strategies to prevent and treat T2D. Exciting recent developments have shown that AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein kinase, acts as an integrator of regulatory signals monitoring systemic and cellular energy balance, thus providing the emerging concept, as first suggested by Winder and Hardie in ( ) , that AMPK is an attractive therapeutic target for intervention in many conditions of disordered energy 1999 Winder and Hardie 1999 balance including T2D and insulin resistance.
Rational for a pharmacological management of T2D by targeting AMPK
Physical activity is an important determinant to prevent and control T2D. Current guidelines recommend practical, regular and moderate regimens of physical activity. The multiple metabolic adaptations that occur in response to physical activity can improve glycaemic control for individuals with T2D or delay the onset of the disease. Indeed, it is now recognized that beneficial effects of physical activity are still maintained in insulin resistant populations. This suggests that some metabolic actions of exercise (as increase in muscular glucose uptake) are dependent of specific intracellular pathways that bypass signalling altered by insulin resistance. In consequence, any drug inducing favourable changes similar to those of physical exercise on whole body metabolism are attractive candidates for treatment and prevention of obesity, metabolic syndrome and T2D. Interestingly, it is now well established that muscle contraction is a prototypical AMPK activator ( ). Thus, it is expected that part of the effect of physical activity in preventing the development of Hayashi et al. 1998 metabolic disorders related to a sedentary lifestyle is due to activation of AMPK. Indeed, it has been documented that pharmacological AMPK activation may recapitulate some of the exercise-induced short-term adaptations and is likely to mediate beneficial effects of exercise on insulin sensitivity and glucose transport in skeletal muscle ( ; ). In addition, Bergeron et al. 1999 Fisher et al. 2002 pharmacological AMPK activation resulted in long-term adaptation similar to those induced by endurance exercise training with the induction of genes linked to oxidative metabolism and enhanced running endurance ( ). Narkar et al. 2008 In the Diabetes Prevention Program (DPP) the incidence of diabetes was reduced by 58 with a low-calorie, low-fat diet, as compared % with placebo after 3 years of follow-up ( ). The beneficial effect of calorie restriction in reducing T2D incidence was Knowler et al. 2002 confirmed by other clinical studies ( ; ). In overweight and obese humans, calorie restriction Pan et al. 1997 Tuomilehto et al. 2001 improves glucose tolerance, lipid profile and insulin action and reduces mortality associated with T2D ( ; Hammer et al. 2008 Jazet et al. ; ; ) . In order to produce a metabolic profile similar to those of calorie restriction in 2008 Larson-Meyer et al. Weiss et al. 2006 diabetic patients, there is an increased interest in developing pharmacological agents acting as calorie-restriction mimetics. Such agents " "
could provide the beneficial metabolic, hormonal and physiological effects of calorie restriction without altering dietary intake or experiencing any potential adverse consequences of excessive restriction. To this purpose, phytochemicals mimicking the effects of calorie restriction (polyphenols) were recently identified as potent activators for AMPK and ( ; ; in vitro in vivo Baur et al. 2006 Collins et al. 2007 ). Zang et al. 2006 Additionally, it is now recognized that a dysfunction in AMPK signalling pathway might have sustained, deleterious effects at the systemic levels and might contribute to the events that lead to the metabolic syndrome. It is interesting to note that there is a strong correlation between low activation state of AMPK with metabolic disorders associated with insulin resistance, obesity and sedentary activities ( ; ; ; ). Recent studies showed that AMPK is likely to be Lee et al. 2005a Lee et al. 2005b Luo et al. 2005 Martin et al. 2006 under both endocrine and autocrine control in rodents. Thus, in addition to exercise and starvation, AMPK is activated by the fat-cell-derived hormones adiponectin and leptin ( ; ; ) and interleukin-6 Minokoshi et al. Tomas et al. 2002 Yamauchi et al. 2002 (IL-6) (
). Conversely, AMPK activity is suppressed in muscle and liver by sustained hyperglycaemia, in liver by Kelly et al. 2004 re-feeding after starvation ( ) and by increases in the plasma concentration of others adipocyte-derived hormones, resistin Assifi et al. 2005 ( ) and tumor necrosis factor-(TNF-) ( ). In addition to its role in the periphery, AMPK also Banerjee et al. 2004 α α Steinberg et al. 2006 regulates energy intake and body weight by mediating opposing effects of anorexigenic and orexigenic signals in the hypothalamus (   ;  ;  ; ). In addition, many therapies that are useful in treating Andersson et al. 2004 Kim et al. 2004 Kola et al. 2005 Minokoshi et al. 2004 the metabolic syndrome and associated disorders in humans, including TZDs ( ; ), metformin ( Fryer et al. 2002 Saha et al. 2004 , calorie deprivation and exercise, have been shown to activate AMPK system. Lastly, the development of transgenic and knockout 2001 (KO) mouse models (see below) have made possible to better understand the physiological role of AMPK and confirm that disruption of AMPK pathway in various tissues induces various phenotypes mimicking the metabolic syndrome observed in humans.
Taken together the physiological functions of AMPK and the suspected role of AMPK in metabolic disorders, activation of AMPK pathway appears as a promising tool to prevent and/or to treat metabolic disorders.
Structure and regulation of AMPK
AMPK is a major regulator of cellular and whole-body energy homeostasis that coordinates metabolic pathways in order to balance nutrient supply with energy demand. Activation of AMPK switches off ATP-consuming anabolic pathways and switches on ATP-producing catabolic pathways ( ). This would typically occur when AMPK is activated as a result of energy Viollet et al. 2003 deprivation linked to alterations of the intracellular AMP/ATP ratio (e.g., hypoxia, glucose deprivation, muscle contraction), changes in calcium concentration as well as the action of various adipocytokines. AMPK is composed of three different subunits , and appearing It has been confirmed in large scale epidemiological and interventional studies that regular physical activity is of great benefit for the metabolic control of subjects with metabolic syndrome or impaired glucose tolerance or T2D ( ; ; Knowler et al. Pan et al. 1997 ). Although appropriate diet and exercise regimes should therefore be the first choice of treatment and prevention of Tuomilehto et al. 2001 type 2 diabetes, in some patients such management is not appropriate for other medical reasons, or when compliance is difficult because of social factors or poor motivation. In these cases, drugs that act on the signalling pathways involved in physical activity are attractive candidates for treatment and prevention. It is now clearly demonstrated that AMPK is activated by physical training in an intensity-dependent manner both in humans and in rodents ( ). AMPK activation during muscle contraction is a Steinberg and Kemp 2009 physiological adaptation in front of increased energy demand and ATP turnover. It has been demonstrated that AMPK activation may recapitulate some of the exercise-induced adaptations and is likely to mediate beneficial effects of exercise not only on insulin sensitivity and glucose transport in skeletal muscle ( ) but also for additional metabolic benefits coming from AMPK activation by Fisher et al. 2002 exercise in liver and in adipose tissue ( ). Conversely, it has also been demonstrated that disruption of muscular AMPK Park et al. 2002 signalling can be a key factor in the pathophysiology of metabolic disorders. Indeed, reduction of muscular AMPK activity exacerbates the development of insulin resistance and glucose intolerance during high-fat feeding, disturbs muscle energy balance during exercise (as indicated by a reduced muscular ATP content during muscle contraction) and abolishes mitochondrial biogenesis ( ; Fujii et al. 2008 ;  ). Jorgensen et al. 2005 Zong et al. 2002 As a proof of concept, studies with AMPK activators in animal models of T2D have provided promising results. The first evidence came from treatment with the pharmacological compound AICAR (5-amino-imidazole-4-carboxamide-1 D-ribofuranoside, in vivo β metabolized to ZMP which is an analog of AMP) of various animal models of insulin resistance, causing improvement in most, if not all, of the metabolic disturbances of these animals ( ; ; ; ; Bergeron et al. 2001a Buhl et al. 2002 Iglesias et al. 2002 Pold et al. 2005 . In addition, long-term AICAR administration prevents the development of hyperglycaemia in Zucker diabetic fatty (ZDF) rats, 2002 improves peripheral insulin sensitivity in skeletal muscle and delays -cell dysfunction associated with type 2 diabetes ( ).
β Pold et al. 2005 AICAR increases muscle glucose uptake concomitantly with glucose transporter 4 (GLUT4) translocation to the plasma membrane in insulin-resistant animal models and in humans ( ; ; ). Interestingly, Koistinen et al. 2003 Kurth-Kraczek et al. 1999 Merrill et al. 1997 AMPK-induced glucose transport occurs through a mechanism distinct from that utilized by the classical insulin signalling pathway because it is not blocked by inhibitors of phosphatidylinositol 3-kinase, and also because the effects of insulin and AMPK activators are additive (
). This metabolic improvement can be also explained partly by increased expression of specific muscle Hayashi et al. 1998 proteins mimicking some of the effects of exercise training following chronic pharmacological activation of AMPK . Thus, AICAR in vivo or chronic intake of the creatine analogue -guanadinopropionic acid ( -GPA, which competitively inhibits creatine uptake and lowers β β ATP content) ( ) in rodent increases muscle expression of glucose transporter GLUT4 and hexokinase II, an effect Bergeron et al. 2001b partly mediated by the transcriptional coactivator peroxisome proliferator-activated receptor-coactivator-1 (PGC-1 ) (
). It has been proposed that the development of skeletal muscle insulin resistance may be partly linked to 1999 Michael et al. 2001 decreased mitochondrial density ( ). Interestingly, chronic activation of AMPK with AICAR or -GPA increases Petersen et al. 2003 β mitochondrial content and expression of mitochondrial proteins, leading to a mitochondrial biogenesis ( ; Bergeron et al. 2001b Winder et ;  ). All of these data argue for AMPK as a key factor for the metabolic adaptation of skeletal muscle to physical al. Zong et al. 2002 exercise. Supporting this, the effects of chronic activation of AMPK mimicking physical activity on gene expression and mitochondrial biogenesis are abolished in AMPK 2 knock-out (KO) and mAMPK-KD (transgenic mice overexpressing a kinase-dead AMPK 2 mutant critical regulators of genes encoding electron chain complexes) ( ). Another critical factor for mitochondrial Bergeron et al. 2001b biogenesis is the inducible coactivator of nuclear receptors, PGC-1 . Regulation of PGC-1 by AMPK is complex. First, it has been α α demonstrated that AMPK directly phosphorylates and activates PGC-1 ( ). In addition, activated PGC-1 in turn α Jager et al. 2007 α increased the expression of PGC-1 and of mitochondrial oxidative genes (cytochrome c, uncoupling protein 1). Interestingly, PGC-1 α α activity and expression are reduced in type 2 diabetes in humans ( ). Thus, AMPK activators could be used in order to Mootha et al. 2003 reverse this defect. Additionally, activation of AMPK in response to physical exercise has been also observed in extra-muscular tissues such as liver and adipose tissue ( ) and might accounted for additional metabolic benefits. Physical training increases Park et al. 2002 circulating adiponectin and mRNA expression of its receptors in muscle, which may mediate the improvement of insulin resistance and the metabolic syndrome in response to exercise by activation of AMPK.
Lastly, increase in blood supply is critical for physiological adaptation during physical activity. Vasodilatation is a vital mechanism of systemic blood flow regulation that occurs during periods of increased energy demand. Thus, because AMPK plays a central role in the adaptation to metabolic stress, it is tempting to speculate that AMPK could be involved in the regulation of metabolic vasomotion. It is well known that moderate-intensity exercise increases nitric oxide synthase (NOS) activity ( ). Interestingly, it has been Roberts et al. 1999 recently reported that mAMPK-KD mice are unable to increase total NOS activity during moderate-intensity exercise and may cause an ). This indicates how changes in tissue metabolism can direct blood flow according to demand. Lee-Young et al. 2009 In addition, the lower skeletal muscle capillarization in mAMPK-KD mice might also contribute to the reduced blood flow during exercise ( ). Nitric oxide (NO) plays a fundamental role in vascular homeostasis and it has been suggested that impaired NO Zwetsloot et al. 2008 efflux from contracting mAMPK-KD mice suppressed exercise-induced vascular relaxation ( ). Furthermore, it has Lee-Young et al. 2009 suggested that AMPK activation is in part regulated by endogenous NO in a positive feedback mechanism, such that increase NO activates AMPK, which further augments NOS activity and NO production ( ; ). Accordingly, the exercise-induced Lira et al. Zhang et al. 2008 increase in AMPK signalling was ablated in skeletal muscle of eNOS KO mice (Lee-Young et al.) . Therefore, AMPK-eNOS interaction might play an important role in the adaptation processes during exercise in order to maintain cellular energy levels by amending vascular function.
Mimicking the beneficial effects of calorie/dietary restriction
Excessive calorie intake increases the risk of developing chronic disease such as obesity, metabolic syndrome, T2D, systemic low grade inflammation, cardiovascular event and premature mortality. Conversely, calorie restriction improves glucose tolerance and insulin action and reduces mortality linked to type 2 diabetes and cardiovascular diseases ( ; ; Hammer et al. 2008 Jazet et al. 2008  ). Because it is difficult to maintain long-term calorie restriction in modern society, there has been an et al. Weiss et al. 2006 increased interest in developing pharmacological agents that act as calorie-restriction mimetics. Among them, plant-derived polyphenolic
compounds, such as resveratrol (which is present in grapes, peanuts, and several other plants) were first recognized as mimicking the effects of calorie restriction in lower eukaryote ( ). Additionally, resveratrol administration prevents the deleterious Howitz et al. 2003 effects of high calorie intake on insulin resistance and metabolic syndrome components in rodents ( ; ; Baur et al. 2006 Lagouge et al. 2006 ; ; ). Resveratrol has been described as a potent activator of the NAD( )-dependent Milne et al. 2007 Sun et al. 2007 Zang et al. 2006 + deacetylases sirtuins including SIRT1, one of the seven mammalian sirtuin genes ( ). However, recent findings indicate Howitz et al. 2003 that resveratrol is not direct SIRT1 activator ( ). Resveratrol, like other polyphenols, also activates AMPK ( Pacholec et al. 2010 Baur et al. deleterious effects of insulin resistance on energy balance and metabolic homeostasis. Thus, SIRT1 activation increases hepatic insulin sensitivity, decreases whole-body energy requirements ( ; ) promotes adaptation of insulin secretion Banks et al. 2008 Sun et al. 2007 during insulin resistance development ( ; ) and coordinates lipid mobilization and utilization ( Bordone et al. 2006 Moynihan et al. 2005 ). The knowledge of SIRT1 action at the molecular level has been more delineated by using chronic treatments with Picard et al. 2004 resveratrol and it has been suggested that SIRT1 promotes LKB1-dependent AMPK stimulation through the direct deacetylation and activation of LKB1 ( ; ). Thus, polyphenols as resveratrol are now recognized as compounds with potential Hou et al. Lan et al. 2008 great interest to improve and/or delay or prevent metabolic disorders linked to western life style by activating the complementary metabolic stress sensors SIRT1 and AMPK ( ). Accordingly, it has been recently established that AMPK acts as the prime Canto et al. 2009 initial sensor for fasting-induced adaptations in skeletal muscle and that SIRT1 downstream signalling was blunted in the absence of
AMPK (
). In addition, recent studies demonstrated that resveratrol failed to increase the metabolic rate, insulin Canto et al. 2010 sensitivity, glucose tolerance, mitochondrial biogenesis and physical endurance in the absence of either AMPK 1 or AMPK 2 ( α α Um et al. ) . 2010
Mimicking the beneficial effects of hypoglycaemic agents AMPK action in liver T2D is the result of an imbalance between glucose production and glucose uptake by peripheral tissues. Elevated hepatic glucose production is a major cause of fasting hyperglycaemia in diabetic subjects ( ). From various effectors, AMPK Saltiel and Kahn 2001 signalling is a key factor that control hepatic glucose production. Indeed, systemic infusion of AICAR in normal and insulin-resistant obese rats leads to the inhibition of hepatic glucose production ( ). Additionally, short-term hepatic expression of a Bergeron et al. 2001a constitutively active form of the 2 catalytic subunit (AMPK 2-CA) leads to mild hypoglycaemia in normal mice ( ; which is known to mediate CREB-dependent transcription of PGC1 and its subsequent gluconeogenic targets PEPCK and G6Pase genes. mice and in adiponectin treated rodents ( ; ) suggesting that hepatic AMPK is specifically a Banerjee et al. 2004 Yamauchi et al. 2002 target of both adipocytokines, the former acting as an AMPK inhibitor, the latter as an activator. This was also demonstrated by lack of systemic adiponectin infusion effect on hepatic glucose production in liver-specific AMPK 2 KO mice ( ). 
AMPK action in skeletal muscle
After a meal or during the euglycaemic hyperinsulinemic clamp, both situations with high circulating levels of insulin, skeletal muscle is the main site for glucose disposal in the body. This is sustained by the insulin-dependent translocation of glucose transporter GLUT4
from intracellular vesicles to the cell surface, which is impaired in T2D patients. As described above, it has been clearly demonstrated that muscular AMPK activation, either by exercise or by AICAR, stimulates muscle glucose uptake. Interestingly, even if AMPK and insulin acts through phosphorylation of downstream target of Akt (Akt substrate of 160kDa, AS160) ( ), AMPK-dependent and Dreyer et al. 2008 insulin-dependent GLUT4 translocation are distinct pathways ( ). Additionally, exercise-induced muscular AMPK Treebak et al. 2007 activation and AS160 phosphorylation are both reduced in obese non-diabetic and obese type 2 diabetes subjects ( ) but Musi et al. 2001 maintained in lean type 2 diabetes patients ( ) suggesting that dysregulation of muscular AMPK is more dependent of Bruce et al. 2005 obesity than of hyperglycaemia. Discovery of muscular AMPK activators in order to mimic regular physical activity metabolic effects is an important challenge. It was first demonstrated that some adipokines stimulate glucose transport in skeletal muscle in an AMPK-dependent manner. Indeed, leptin is known to stimulate glucose uptake in peripheral tissue ( ; Kamohara et al. adipokine, has also been shown to increase glucose transport in both lean and obese skeletal muscle, although the effect was less significant in obese skeletal muscle ( ). It has also recently been recognized that IL-6 (also called myokine " " Febbraio and )) is released acutely from the skeletal muscle during prolonged exercise, activates AMPK and improves peripheral glucose Pedersen 2005 uptake and insulin sensitivity at the whole body level ( ). In contrast, chronic exposure of IL-6 (as observed in obesity) Glund et al. 2007 promotes insulin resistance both and ( ). The dual effect of IL-6 on insulin sensitivity probably in vitro in vivo Nieto-Vazquez et al. 2008 explains some conflicting results recently discussed in more details elsewhere ( ). Importantly, it has been also Nieto- Vazquez et al. 2008 suggested that AICAR, in addition to activating AMPK, suppresses chronic IL-6 release by an AMPK independent mechanism in insulin-resistant models (
). This strongly suggested that AMPK activators can act at a multi-tissular level in order to Glund et al. 2009 restore metabolic inter-organs cooperation. phosphorylates and activates at least 12 AMPK-related kinases. These data raised the question whether the glucose-lowering function of LKB1 is mediated by AMPK-related kinases rather than AMPK itself.
Because circulating levels of adiponectin are decreased in individuals with obesity and insulin resistance, adiponectin replacement in humans may be a promising approach. It has been demonstrated that full-length adiponectin activates AMPK in the liver, while globular adiponectin did so both in muscle and the liver ( ). Blocking AMPK activation by the use of a dominant negative Yamauchi et al. 2002 mutant inhibited the action of full length adiponectin on glucose hepatic production ( ). In addition, lack of action of Yamauchi et al. 2002 adiponectin on hepatic glucose production when AMPK 2 catalytic subunit is missing, strongly supports the concept that adiponectin α effect is strictly dependent on AMPK ( ). Awaiting adiponectin analogs development, alternative ways to restore Andreelli et al. 2006 adiponectin effects have been suggested recently. Improved metabolic disorders following TZDs administration are in part mediated through adiponectin-dependent activation of AMPK since activation of AMPK by rosiglitazone treatment is diminished in adiponectin KO mice ( ). TZDs can markedly enhance the expression and secretion of adiponectin and through the Nawrocki et al. 2006 in vitro in vivo activation of its promoter and also antagonize the suppressive effect of TNF-on the production of adiponectin ( ). ) while no change in serum adiponectin concentration or adipocyte adiponectin content was found in type 2 diabetic patients treated with metformin ( ). Phillips et al. 2003 AMPK action in -cells β β-cell failure is a strong determinant in the pathogenesis of type 2 diabetes. This defect inexorably aggravates with time as demonstrated in prospective clinical studies (1995) . According to the glucolipotoxicity hypothesis ( ) chronic high Prentki et al. 2002 glucose dramatically influences -cell metabolism. Indeed, it has been observed in high glucose condition an increase of cytosolic fatty β acyl-CoA partitioning toward potentially toxic cellular products (e.g., diacylglycerol, ceramide and lipid peroxides) leading to impaired insulin secretory response to glucose and ultimately apoptosis ( ). Indeed, decrease in -cell mass is likely to play a role Donath et al. 2005 β in the pathogenesis of human type 2 diabetes ( ) as it does in rodent models of the disease ( ; Butler et al. 2003 Kaiser glucose-stimulated insulin secretion ( ). This could be considered as a deleterious effect of AMPK activation. But it is Sun et al. 2010 hypothesized that pharmacological activation of AMPK and its subsequent decrease in insulin secretion, could be appropriate in insulin resistant conditions characterized by high insulin levels. Indeed, it has been suggested that reduction of the pathological hyperinsulinemia is potentially a mechanism to protect -cell mass. Consistent with this assumption, systemic AICAR infusion in prediabetic Zucker fatty β rats prevented the development of hyperglycaemia and preserved -cell mass ( ).
β Pold et al. 2005 Taken together, these data suggest that AMPK is an emergent factor that could protect by different ways -cell function and -cell β β mass from the deleterious effects of glucolipotoxicity.
Mimicking the beneficial effects of hypolipidemic agents
Dyslipidemia of both insulin resistance and type 2 diabetes is a recognized risk factor for cardiovascular disease. Diabetic dyslipidemia is a cluster of potentially atherogenic lipid and lipoprotein abnormalities that are metabolically interrelated. Activated AMPK inhibits cholesterol and fatty acid synthesis. Thus, AMPK suppresses expression of lipogenesis-associated genes such as fatty acid synthase, pyruvate kinase and acetyl CoA carboxylase (ACC) ( ; ; ; Foretz et al. 2005 Foretz et al. 1998 Leclerc et al. 1998  ), and 3-Hydroxy ). These data emphasize the critical role for AMPK in the control of hepatic lipid deposition via Andreelli et al. 2006 decreased lipogenesis and increased lipid oxidation, thus improving lipid profile in type 2 diabetes.
It is well documented that changes in adipose tissue mass are frequently associated with alterations in insulin sensitivity (Eckel et al. ; ). AMPK evidenced recently as a regulator of fat mass. Hormone sensitive lipase (HSL), one of the key protein responsible for the lipolytic activity, is activated by PKA phosphorylation at serines 563, 659 and 660 ( ). AMPK reduces this activation through phosphorylation at serine 565 ( Anthonsen et al. 1998 Garton et al. ;  ). This effect has been demonstrated both in white adipocytes and in skeletal muscle in both resting and 1989 Garton and Yeaman 1990 contracting conditions (  ;  ;  ) . Thus, inhibition of HSL by AMPK represents a Muoio et al. 1999 Smith et al. 2005 Watt et al. 2006 mechanism to limit this recycling and ensure that the rate at which fatty acids are released by lipolysis does not exceed the rate at which they could be disposed of by export or by internal oxidation.
Beyond its hypolipidemic properties, AMPK system can be also a regulator of ectopic lipids metabolism. Depot of lipids in tissue is a hallmark defect in metabolic syndrome in humans. According to this lipotoxicity hypothesis, insulin resistance develops when excess lipids are deposited in insulin-sensitive cell types. The balance between lipids oxidation and lipids storage in cells is mainly regulated by malonyl-CoA, generated by ACC. Malonyl-CoA is known to inhibit transport of fatty acids into mitochondria via allosteric regulation of carnitine palmitoyltransferase-1, thereby preventing them from being metabolized. Activated AMPK inhibits malonyl-CoA synthesis and shifts the balance towards mitochondrial fatty acid oxidation and away from fat storage. Several studies have shown that activation of AMPK with AICAR, -lipoic acid, leptin, adiponectin and IL-6 enhances muscle fatty acid oxidation ( ;
Carey et al. Lee et al. 2005b ; ; ; ). Chronic leptin treatment increases skeletal muscle fatty acid Merrill et al. 1997 Minokoshi et al. 2002 Yamauchi et al. 2002 oxidation in an AMPK-dependent manner by increasing AMP/ATP ratio in oxidative muscle fibers and by increasing AMPK 2 nuclear the activating AMPK 3 R225Q mutation in muscle increased fatty acid oxidation and protected against excessive triglyceride γ accumulation and insulin resistance in skeletal muscle ( ). Interestingly, recent data have shown that resistin lowers Barnes et al. 2004 AMPK signalling in muscle cells and that this reduction is associated with suppressed fatty acid oxidation ( ).
Palanivel and Sweeney 2005
Non-alcoholic fatty liver disease is a serious consequence of obesity increasing the risk of liver cancer or cirrhosis. The origin of this disease is unknown and probably multifactorial. Nevertheless, because insulin resistance is recognized as an associate and/or promoting mediator of the disease, management of insulin resistance becomes an important challenge. For this specific point and because AMPK is a key factor in lipids partitioning (balance between synthesis and oxidation), management of non-alcoholic fatty liver disease by activators of AMPK represents a new therapeutic strategy. Adiponectin treatment restores insulin sensitivity and decreases hepatic steatosis of obese mice (
). This effect is linked to an activation of AMPK in the liver that decreases fatty acid biosynthesis and increases Xu et al. 2003 mitochondrial fatty acid oxidation ( ). Reduction of liver steatosis when AMPK is activated has been also confirmed Yamauchi et al. 2001 by a decrease in liver triglyceride content in lean and obese rodents during AICAR infusion ( ; ) and Bergeron et al. 2001a Cool et al. 2006 after treatment with small-molecule AMPK activators ( ). The synthesis of triglycerides is regulated by both the supply of Cool et al. 2006 glycerol-3-phosphate (from carbohydrate metabolism) and of fatty acyl-coenzyme A. The first step of triglycerides synthesis is catalyzed by glycerol-3-phosphate acyl-transferase (GPAT). AICAR or exercise induced AMPK activation reduces hepatic GPAT activity and triglycerides esterification ( ; ). Fasting, that increases hepatic AMPK inhibits GPAT activity ( Muoio et al. 1999 Park et al. 2002 ). In the same way, AMPK activation by resveratrol protects against lipid accumulation in the liver of diabetic mice ( al. 1994 Zang et al. ) in association with increased mitochondrial number ( ) and SIRT1-dependent deacetylation of peroxisome 2006 Baur et al. 2006 proliferator-activated receptor coactivator (PGC)-1 , a master regulator of mitochondrial biogenesis ( ; α Baur et al. 2006 Rodgers and ) . The efficacy of metformin as a treatment for fatty liver disease has been confirmed in obese, mice, which develop Puigserver 2007 ob/ob hyperinsulinemia, insulin resistance and fatty livers ( ). Lin et al. 2000 The discovery of new strategies of management of hepatic steatosis in humans is of considerable interest. AMPK activation could be one of them as suggested by recent clinical studies in type 2 diabetic patients. Indeed, it has been demonstrated that AICAR infusion results in significant decline in circulating plasma non-esterified fatty acids (NEFA) levels, suggesting stimulation of hepatic fatty acid oxidation and/or a reduction in whole body lipolytic rate ( ). Management of hepatic steatosis by targeting AMPK is also Boon et al. 2008 suggested by recent successes in treating this disorder with diet, exercise, and TZDs all known as AMPK activators ( ; Carey et al. 2002 ).
Other studies are needed to analyze the beneficial effect of AMPK activation for the Neuschwander-Tetri and Caldwell 2003 management of fatty liver diseases in humans.
Mimicking the beneficial effects of an anti-obesity drug
Weight reduction is best achieved by behavioural change to reduce energy intake and by increasing physical activity to enhance energy expenditure. Therefore, the AMPK system may be an important pharmacological target to reduce fatty acid storage in adipocytes and to treat obesity. By inducing fatty acid oxidation within the adipocyte, activation of AMPK would reduce fat cell size and also prevent fatty acids from being exported to peripheral tissues and cause deleterious effects. Direct evidence linking AMPK activation to diminished adiposity was first obtained by chronic administration of AICAR to lean and obese rats, an effect attributable, at least in part, to an increase in energy expenditure ( ; ). Furthermore, the anti-obesity hormone leptin increases fatty-acid Buhl et al. 2002 Winder et al. 2000 oxidation in skeletal muscle by activating AMPK (this process involves an increase in the AMP/ATP ratio) ( ), Minokoshi et al. 2002 depletes body fat stores by activating AMPK activity and by increasing uncoupling mitochondrial protein (UCP)-1 and UCP-2 expression ( ). 3-adrenoceptor ( 3-AR) agonists were also found to have remarkable anti-obesity and anti-diabetic effects in rodents Orci et al. 2004 β and these compounds were found to stimulate AMPK in fat cells ( ). In addition, overexpression of UCP-1 in Moule and Denton 1998 adipocytes leads to an increase in the AMP/ATP ratio and activation of AMPK, inactivation of ACC and a decreased lipogenesis ( ). Additionally, a strong mitochondrial biogenesis in response to increased UCP-1 expression in adipocytes has been Matejkova et al. 2004 demonstrated ( ; ) , features that could enhance the fatty acid oxidation capacity of adipocytes in Orci et al. 2004 Rossmeisl et al. 2002 response to AMPK activation. During chronic AICAR treatment, activated AMPK increases UCP-3 expression in muscle independently of changes in mitochondrial biogenesis ( ; ). This effect can also explain changes in energy expenditure Stoppani et al. 2002 Zhou et al. 2000 during AMPK activation.
Benefits of targeting AMPK pathway for metabolic complications AMPK and ischemic heart
Type 2 diabetes is recognized as an important risk factor for cardiovascular diseases and mortality. In ischemic heart, balance between glucose and lipids is altered. In this situation, activation of AMPK is considered as a metabolic adaptation to rescue energy supply. Indeed, AMPK stimulates glycolysis and sustains energy supply during ischemic stress. Convincing evidence suggests that the more AMPK is activated in ischemic myocardial tissue, the more the size of infarcted tissue is reduced. Because the size of myocardial infarcted tissue is one of the variables that determine the risk of sudden death and the risk of cardiac insufficiency in humans, reduction of the volume of ischemic tissue is an important therapeutic challenge. Thus, promotion of glucose oxidation or inhibition of fatty acid oxidation in ischemic/reperfused hearts could be a promising novel therapeutic approach during myocardial ischemia. Such a mechanism has been demonstrated during the phenomenon called ischemic preconditioning. This phenomenon (consisting in repeated brief episodes of myocardial ischemia) ( ) induces endogenous protective mechanisms in the heart which becomes more resistant to Murry et al. 1986 subsequent ischemic episodes. The molecular mechanism of this protective effect is based on AMPK activation in a PKC-dependent manner and promotion of glucose utilization in myocardial cells ( ). Attractively, adiponectin protects the heart from Nishino et al. 2004 ischemia by activating AMPK and increasing the energy supply to heart cells ( ). For example, high blood levels of Shibata et al. 2005 adiponectin are associated with a lower risk of heart attack, and vice versa ( ). Additionally, adiponectin levels rapidly Pischon et al. 2004 decline after the onset of acute myocardial infarction. Similarly, in mice, deletion of adiponectin induces increased heart damage after reperfusion that was associated with diminished AMPK signalling in the myocardium ( ). In addition, it has also been Shibata et al. 2005 reported that adiponectin attenuated cardiac hypertrophy through activation of AMPK signalling pathway ( ; Liao et al. 2005 Shibata et al. ) . These findings clearly show that adiponectin has a cardioprotective role during ischemia through AMPK-dependent 2004a in vivo mechanisms.
Since AMPK regulates the balance between glucose and fatty acid metabolism at the cellular level, the metabolic response of the heart to global ischemia was studied in AMPK 2 / mice. These hearts displayed a more rapid onset of ischemic contracture, which was α − − associated with a decrease in ATP content, in lactate production, in glycogen content and in the phosphorylation state of ACC ( ). Importance of metabolic adaptation via AMPK activation during ischemia was also documented in another Zarrinpashneh et al. 2006 transgenic mouse model overexpressing a dominant negative form of AMPK 2 in the heart ( ). These studies indicate α Russell et al. 2004 that the 2 isoform of AMPK is required for the metabolic response of the heart to ischemia suggesting that AMPK is cardioprotective.
α Thus, AMPK activators could be of particular interest for the management of myocardial ischemia. Nevertheless, inappropriate activation of AMPK can have deleterious consequences in the heart. Indeed, in humans, a variety of mutations in the 2 subunit ( ) have been γ Figure 1 shown to produce a glycogen storage cardiomyopathy characterized by ventricular pre-excitation, conduction defects and cardiac hypertrophy ( ). This argues for a restrictive use of AMPK activators during the acute phase of heart ischemia Dyck and Lopaschuk 2006 and not for a chronic activation of cardiac AMPK. Thus, the balance between benefits and deleterious cardiac effects of AMPK activation has to be studied in more details.
AMPK and endothelial dysfunction
Endothelial cell dysfunction, as manifested by impaired vascular relaxation or an increase in circulating vascular cell adhesion molecules, is present in patients with type 2 diabetes, and it is thought to be one component of the inflammatory process that initiates atherogenesis ( ). Based on studies using genetically modified mice, the production of NO via eNOS is crucial in the Van Gaal et al. 2006 regulation of vascular tone ( ; ). The activity of eNOS is largely determined by posttranslational Lau et al. 2000 Maxwell et al. 1998 modifications such as multisite phosphorylation and protein interactions. Interestingly, AMPK enhances eNOS activity by direct phosphorylation of Ser1177 ( ; ), Ser633 ( ) and by promoting its association with heat Chen et al. Chen et al. 1999 Chen et al. 2009 shock protein 90 ( ) leading to endothelial NO production. In this respect, metformin has been proposed to improve Davis et al. 2006 endothelium function in diabetes by favouring phosphorylation of eNOS by AMPK activation ( ). Metformin was also Davis et al. 2006 shown to relax endothelium-denuded rat aortic rings pre-contracted with phenylephrine, showing that AMPK can induce vasorelaxation in an endothelium-and NOS-independent manner ( ). Accordingly, AMPK activation in response to hypoxia Majithiya and Balaraman 2006 or metabolic challenge can induce vasorelaxation of big vessels ( ; ), thereby favouring blood flow. Evans et al. 2005 Rubin et al. 2005 Interestingly, AMPK-dependent adiponectin vascular effects have been demonstrated for angiogenic repair in an ischemic hind limbs model (
). Similarly, -lipoic acid improves vascular dysfunction by normalizing triglyceride and lipid peroxide levels Shibata et al. 2004b Page / 9 14 and NO synthesis in endothelial cells from obese rat by activating AMPK ( ). Attractively, adiponectin exhibits potent Lee et al. 2005a anti-atherosclerotic effects and suppresses endothelial cell proliferation via AMPK activation ( ; ). Kubota et al. 2002 Yamauchi et al. 2003 Beyond the vascular effects of AMPK activation, it has been recently demonstrated that AMPK can regulate blood pressure. Thus, long-term administration of AICAR reduces systolic blood pressure in an insulin-resistant animal model ( ). In this Buhl et al. 2002 process, a potential role for AMPK could be the regulation of ion channels or sodium cotransporters including ENaC and the Na-K-2Cl cotransporter ( ; ). These data provide additional support to the hypothesis that AMPK activation Carattino et al. 2005 Fraser et al. 2003 might be a potential future pharmacological strategy for treating the cardiovascular risk factors linked to the metabolic syndrome.
Conclusion
Lifestyle modifications are recognized as an important preventive and therapeutic intervention for impaired glucose tolerance, insulin resistance and type 2 diabetic patients. AMPK activators are potential new therapeutic agents for the treatment of type 2 diabetes by mimicking the beneficial effects of physical activity and of calorie restriction. Accordingly, AMPK-activating agents could also be used as regulators of hyperglycaemia, obesity, lipids disorders, lipotoxicity and cardiovascular risk by targeting specific cellular pathways ( Figure   ) . Resveratrol, metformin, TZDs, adiponectin and leptin are now considered as AMPK activators. However, many other effects of 3 AMPK activation should be carefully evaluated and many questions are not resolved: are new AMPK activators tissue specific? What are the consequences of a long term pharmacological AMPK activation? Additional studies are required to address these critical points. 
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Figure 2
Regulation of AMPK by upstream kinases and phosphatases The major upstream kinase is a complex between the tumour suppressor kinase LKB1 and two accessory subunits, STRAD and MO25 which appears to be constitutively active. The CaMKK could also phosphorylate Thr-172 and activate AMPK following a rise in cytosolic Ca . A β 2 + third potential upstream kinase is TAK1 but its physiological significance is uncertain. Thr-172 phosphorylation is removed by PP2C
phosphatase. Physiological, hormonal and pharmacological stimulatory effectors of AMPK complex are listed.
Figure 3
AMPK, a potential therapeutic target in metabolic disease AMPK pathway has become the focus of a great deal of attention as a novel therapeutic target in metabolic disease because it has been demonstrated that physiological and pharmacological activation of AMPK results in remodelling different metabolic pathways. AMPK has several important metabolic effects, mimicking the beneficial effects of exercise, including modulation of lipid metabolism, enhanced muscle glucose uptake, increased mitochondrial biogenesis, improvement in insulin sensitivity and reduction in blood glucose. Activation of AMPK by pharmacological agents presents a unique challenge to prevent and treat the metabolic abnormalities associated with the metabolic syndrome.
